Tirzepatide is a dual GIP and GLP-1 receptor agonist that promotes insulin sensitivity, significant weight loss, and reduces inflammation. Its primary healthspan relevance stems from its profound impact on metabolic health, a cornerstone of longevity, by mimicking the effects of powerful satiety and glucose-regulating hormones.
Verdict
A powerful tool for metabolic health, but requires medical guidance.
HEALTHSPAN IMPACT
Foundational
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$1000 - $1300
Protocol
- Start at 2.5 mg weekly via subcutaneous injection, titrating up slowly based on tolerance and goals.
Flags
- Common side effects include nausea, diarrhea, and constipation, especially during dose escalation.
- Risk of muscle mass loss alongside fat loss; resistance training is crucial.
- Boxed warning for risk of thyroid C-cell tumors based on rodent studies.
- May reduce the efficacy of oral contraceptives due to delayed gastric emptying.
- Requires a prescription and ongoing medical supervision.